Abstract: There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.

Abstract: There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.

Abstract: There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.

Abstract: There is provided wound healing composition which comprises at least one oxidant, at least one photoactivator capable of actuating the oxidant and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin in association with a pharmaceutically acceptable carrier. In addition, a method of topically treating wounds using at least one oxidant and at least one photoactivator capable of activating the oxidant followed by illumination of said photosensitizer is disclosed.

Abstract: There is provided wound healing composition which comprises at least one oxidant, at least one photoactivator capable of actuating the oxidant and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin in association with a pharmaceutically acceptable carrier. In addition, a method of topically treating wounds using at least one oxidant and at least one photoactivator capable of activating the oxidant followed by illumination of said photosensitizer is disclosed.

Abstract: There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.

Abstract: An object (2) mounted on wheels (4) has a grip device (1) of the type wherein a free end (10) of a telescopically extensible supporting structure (8) carries an integral grip portion (9) substantially parallel to an axis of rotation (6) of the wheels (4); according to the invention, the grip portion (9) has first (11) and second (12) articulating means enabling the grip portion (9) to rotate, with respect to the supporting structure (8), about two distinct axes of rotation (13, 14) perpendicular to each other; and angular locking means (33, 34) for preventing rotation of the grip portion (9) with respect to the supporting structure (8), and ensuring firm but reversible connection of the grip portion (9) to the supporting structure (8) in a predetermined mutual position. A third articulating means (35) enables the grip portion (9) to translate along one of the axes of rotation (13).

Abstract: This invention relates to methods and compositions for treating diabetes, which involve the use of hydroxylated amino acids, such as 4-hydroxyisoleucine, and one or more additional antidiabetic agents.

Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring and treating or preventing amyloid-related disease.

Abstract: The method is used for preventing or treating an amyloid-? related disease in a subject. The method comprises administering to a subject in need thereof an effective amount of a first agent that prevents or treats amyloid-? related disease, and a second agent that is (i) a peptide or peptidomimetic that modulates amyloid-? fibril formulation or induces a prophylactic or therapeutic immune response against amyloid-? fibril formulation, or (ii) an immune system modulator that pi-events or inhibits amyloid-? fibril formulation.

Abstract: This invention relates to methods and pharmaceutical compositions for treating amyloid-? related diseases, including Alzheimer's disease. The invention, for example, includes a method of concomitant therapeutic treatment of a subject, comprising administering an effective amount of a first agent and a second agent, wherein said first agent treats an amyloid-? disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement.

Abstract: An object (2) mounted on wheels (4) has a grip device (1) of the type wherein a free end (10) of a telescopically extensible supporting structure (8) carries an integral grip portion (9) substantially parallel to an axis of rotation (6) of the wheels (4); according to the invention, the grip portion (9) has first (11) and second (12) articulating means enabling the grip portion (9) to rotate, with respect to the supporting structure (8), about two distinct axes of rotation (13, 14) perpendicular to each other; and angular locking means (33, 34) for preventing rotation of the grip portion (9) with respect to the supporting structure (8), and ensuring firm but reversible connection of the grip portion (9) to the supporting structure (8) in a predetermined mutual position. A third articulating means (35) enables the grip portion (9) to translate along one of the axes of rotation (13).

Abstract: There is provided cyclic peptides of the general formula where x represents any amino acid sequence or analogues located from amino acid 586 to amino acid 602 gp4l (HIV-1) y represents any amino acid sequence or analogues located from amino acid 611 to amino acid 620 gp4l (HIV-1); and a and b represent the amino and carboxy terminals, respectively, as well as substituents which are effective to make the peptides more useful as an immunodiagnostic reagent. These cyclic peptides alone or in admixture with certain linear peptides are particularly useful in detecting HIV antibodies.

Abstract: There is provided cyclic peptides of the general formula wherein x represents the amino terminus, one amino acid or amino acid sequence starting with amino add 604 and going back as far as amino acid 586 (gp41-HIV-1); and y represents the carboxy terminus, an amino acid or amino acid sequence starting with amino acid 612 and extending up to amino acid 629 (gp41-HIV-1). There is also provided peptides of the general formula wherein x1 represents the amino terminus, one amino acid or amino acid sequence starting with amino add 596 and going back as far as amino acid 578 (gp42-HIV-2) and a and b represent the amino and carboxy terminals, respectively, as well as substituents which are effective to make the peptides more useful as an immunodiagnostic reagent; and y1 represents the carboxy terminus, an amino acid or amino add sequence starting with amino acid 604 and extending up to amino acid 613 (gp42-HIV-2) and a and b are as defined previously.

Abstract: Herein disclosed are N-naphthoylglycine derivatives having aldose reductase inhibiting activity. The derivatives are useful for treating, diabetic complications.

Abstract: Herein disclosed are N-naphthoylglycine derivatives having aldose reductase inhibiting activity. The derivatives are useful for treating diabetic complications.

Abstract: Disclosed herein are tolrestat amides and methods of preparation. The amides are new aldose reductase inhibitors useful for the treatment or prevention of diabetic complications.

Abstract: Disclosed herein are new aldose reductase inhibitors of the formula ##STR1## wherein n is an integer from 1 to 5 and X is a chalcogen, and methods of preparation. The derivatives are useful for treating or preventing diabetic complications.

Abstract: Herein disclosed are N-naphthoylglycine derivatives having aldose reductase inhibiting activity. The derivatives are useful for treating diabetic complications.

Abstract: Herein disclosed are N-naphthoylglycine derivatives having aldose reductase inhibiting activity. The derivatives are useful for treating diabetic complications.